2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2488

Impact of Protocolized Tight Control and Biological Dose Optimization in Daily Clinical Practice: Results of a Pilot Implementation Study

Quality Measures and Quality of Care Poster Session

9:00AM-11:00AM: Abstract Number: 2867

Impact of Timely Versus Delayed Use of Anti-Tumor Necrosis Factor (TNF) Biologics in the Treatment of Psoriatic Arthritis: Results from a Modeling Study

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2771

Impact of Tocilizumab Monotherapy in Patients with Moderate to High Disease Activity: Real-World Analyses from the US Corrona Registry

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2756

Impact of Tocilizumab Monotherapy on Patient-Reported Quality of Life Outcomes in the US Corrona Registry

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2279

Impacts on Work: Arthritis Vs Chronic Joint Symptoms without Arthritis

Epidemiology and Public Health Poster (ARHP)

9:00AM-11:00AM: Abstract Number: 2490

Implementation of Disease Activity Measurement for Rheumatoid Arthritis Patients in an Academic Rheumatology Clinic

Quality Measures and Quality of Care Poster Session

9:00AM-11:00AM: Abstract Number: 2502

Implementation of New Pneumococcal Vaccination Recommendations in an Academic Rheumatology Clinic

Quality Measures and Quality of Care Poster Session

9:00AM-11:00AM: Abstract Number: 2492

Implementation of the Clinical Disease Activity Index to Treat to Target Rheumatoid Arthritis in the Ambulatory Setting: A Plan Do Study Act Quality Analysis

Quality Measures and Quality of Care Poster Session

9:00AM-11:00AM: Abstract Number: 2404

Implications of a Positive Patellar Bulge Sign of Knee Joint Effusion in Patients with Osteoarthritis: Association with MRI Signs of Inflammation and with Increased Rate of 5-Year Total Knee Arthroplasty. Data from the Osteoarthritis Initiative

Osteoarthritis - Clinical Aspects Poster II: Biomarkers, Biomechanics and Health Services Research

9:00AM-11:00AM: Abstract Number: 2583

Important Role of CD11c+ Dendritic Cells in Inflammatory Arthritis

Rheumatoid Arthritis - Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2665

Improved Flare/ Remission Pattern in Rheumatoid Arthritis over the Recent Decades

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2503

Improved Pneumococcal Vaccination in Rheumatoid Arthritis Patients in an Urban Academic Rheumatology Clinic

Quality Measures and Quality of Care Poster Session

9:00AM-11:00AM: Abstract Number: 2292

Improvement in Function and Pain Due to Subacromial Bursitis As Related to Dose of Triamcinolone Acetonide or Methylprednisolone Acetate

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II

9:00AM-11:00AM: Abstract Number: 2340

Improvement in Treat to Target Serum Urate Levels: Preliminary Results from a Comparison Between Two Audits of Management

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 2493

Improvement of Disease Activity and Quality of Care in a Cohort of Rheumatoid Arthritis Patients Treated with Conventional Dmard Therapy Under Treat to Target Recommendations and a Model of Patient-Centered Care

Quality Measures and Quality of Care Poster Session

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].